ABBOTT PARK, Ill. - Abbott has expanded its Pure Bliss by Similac line to include new organic and European-made infant formulas, the company announced today. The new formulas are designed to meet diverse parental preferences for organic ingredients and specific milk types.
The Pure Bliss line now includes Pure Bliss by Similac Irish Farms, which is made with milk sourced from Irish cows and manufactured exclusively at Abbott's facility in Ireland. This addition promises complete nutrition that is easy for babies to digest. Another new product, Pure Bliss by Similac Organic in a 2-fluid ounce ready-to-feed bottle, stands as the only USDA-certified organic liquid infant formula available in select U.S. retail stores.
Misha Pardubicka-Jenkins, vice president of Abbott's Pediatric Nutrition business, stated that more parents are seeking specific types of infant formulas, and the Pure Bliss line aims to cater to these needs with options that include organic, A2 milk, and ready-to-feed formats.
The launch also includes Pure Bliss by Similac Organic with A2 Milk, which uses milk from cows producing A2 beta-casein protein. This type of protein is similar to that found in breast milk and is naturally easy to digest.
Parents looking for these products can find them at major retailers such as Amazon (NASDAQ:AMZN), Target (NYSE:TGT), and Walmart (NYSE:WMT). Availability can be checked through the Similac.com product locator.
Abbott's commitment to providing high-quality infant nutrition is backed by nearly a century of research and development. The company offers a range of formulas to support various dietary needs and preferences, including those for sensitive tummies and food allergies.
Abbott is a global healthcare company with a broad portfolio that includes diagnostics, medical devices, nutritional products, and branded generic medicines. The company employs approximately 114,000 people and operates in over 160 countries.
The information for this article is based on a press release statement from Abbott.
In other recent news, Abbott Laboratories (NYSE:ABT) reported strong second-quarter earnings and revenue, with earnings per share of $1.14 surpassing expectations. The company's revenues of $10.38 billion were primarily driven by the Medical Devices segment. In response to these robust results, Abbott has revised its full-year revenue guidance to an organic growth range of 9.5%-10%, and its EPS guidance has been raised to $4.61-$4.71 from the previous $4.55-$4.70 range.
Abbott Laboratories has also entered a global partnership with Medtronic (NYSE:MDT) to develop a continuous glucose monitoring system, aimed at integrating Abbott's FreeStyle Libre technology with Medtronic's automated insulin delivery and smart insulin pen systems. This collaboration is expected to benefit over 11 million people worldwide who manage their Type 1 or Type 2 diabetes with multiple daily injections of rapid-acting insulin.
On the analyst front, Jefferies has maintained its Hold rating on Abbott shares, with a price target set at $120.00. This rating comes as Jefferies continues to evaluate potential financial implications for Abbott due to ongoing litigation over necrotizing enterocolitis actions against Mead Johnson, a subsidiary of Reckitt Benckiser (LON:RKT). Meanwhile, BTIG reaffirmed its Buy rating and $135.00 price target for Abbott Laboratories, citing the strength of the company's diversified portfolio.
In other company news, Abbott Laboratories has faced legal challenges recently, with nearly 1,000 lawsuits filed against the company and British firm Reckitt Benckiser. The lawsuits allege that the companies failed to adequately warn healthcare providers of increased disease risks when using their infant formula. These are the recent developments for Abbott Laboratories.
InvestingPro Insights
As Abbott (NYSE:ABT) expands its product line with the launch of new organic and European-made infant formulas, investors and consumers alike may be interested in the company's financial health and market position. According to real-time data from InvestingPro, Abbott boasts a substantial market capitalization of $196.09 billion, reflecting its significant presence in the healthcare sector. The company's commitment to innovation and meeting consumer demands is also evidenced by its consistent dividend payments over the last 54 years, a reassuring sign of financial stability for investors.
InvestingPro Tips indicate that Abbott is a prominent player in the Healthcare Equipment & Supplies industry, which aligns with their latest product expansion in infant nutrition. Furthermore, the company operates with a moderate level of debt, allowing for flexibility in funding future growth initiatives like the Pure Bliss by Similac line. While the stock is trading at a high P/E ratio of 35.47, suggesting a premium valuation, Abbott's ability to maintain cash flows that sufficiently cover interest payments is a positive indicator of its financial management.
For investors seeking more detailed analysis and additional insights, there are over 10 InvestingPro Tips available for Abbott, which can be accessed through the dedicated InvestingPro product page.
Overall, Abbott's strategic product line expansion and robust financial metrics may offer a compelling narrative for both current shareholders and potential investors considering the company's stock.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.